Clinically Significant Drug Interactions — MCQs

10 questions

Which of the following combinations does not show synergistic action?

A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?

At toxic doses, zero-order kinetics is seen in which of the following substances?

What is the primary purpose of xenobiotic metabolism?

Which statement best describes first-order kinetics in pharmacokinetics?

A 60-year-old patient with atrial fibrillation is prescribed digoxin. Which of the following is the MOST common EARLY side effect of digoxin?

Which of the following are CYP3A inhibitors?

Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?

Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?

Q10

Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?

Clinically Significant Drug Interactions Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following combinations does not show synergistic action?

A. Streptomycin plus penicillin
B. Rifampicin plus dapsone
C. Penicillin plus tetracycline (Correct Answer)
D. Penicillin plus sulfonamide

Explanation: ***Penicillin plus tetracycline*** - This combination is generally **antagonistic** or **indifferent**, not synergistic. Penicillin is a cell wall synthesis inhibitor that works best on actively growing bacteria, while tetracycline is a bacteriostatic protein synthesis inhibitor that can reduce bacterial growth, thereby diminishing penicillin's effect. - The combination is usually avoided as the **bacteriostatic action of tetracycline** can counteract the **bactericidal action of penicillin**, leading to reduced efficacy, especially in infections requiring rapid bacterial clearance. *Penicillin plus sulfonamide* - This combination can show synergism in some contexts, particularly as sulfonamides inhibit **folate synthesis**, while penicillin inhibits **cell wall synthesis**. - While not a classic synergistic pair for all infections, their mechanisms of action are distinct, and they can sometimes be used together, although specific synergistic effects are more limited compared to other pairs. *Streptomycin plus penicillin* - This is a classic example of **synergistic action**, particularly in conditions like **enterococcal endocarditis**. - Penicillin damages the bacterial cell wall, allowing **streptomycin** (an aminoglycoside) to more easily penetrate the cell and act on ribosomal targets, leading to enhanced bactericidal effect. *Rifampicin plus dapsone* - This combination is a cornerstone of **multi-drug therapy for leprosy**, demonstrating clear synergy against *Mycobacterium leprae*. - **Rifampicin** inhibits bacterial RNA synthesis, and **dapsone** inhibits folate synthesis, attacking different essential bacterial pathways which, when combined, are more effective and reduce the development of resistance.

Question 2: A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?

A. Triamterene
B. KCL
C. Atenolol
D. Clarithromycin (Correct Answer)
E. Amiodarone

Explanation: ***Clarithromycin*** - **Clarithromycin** is a **macrolide antibiotic** known to inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system and **P-glycoprotein**. - This inhibition leads to decreased metabolism and **efflux of digoxin**, resulting in **increased serum digoxin levels** and enhanced toxicity. - Among the options, clarithromycin is the **most common cause** of elevated digoxin levels through P-gp inhibition. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that can increase serum potassium. - **Hyperkalemia** generally *reduces* the binding of digoxin to Na+/K+-ATPase, thereby potentially *reducing* its toxic effects. - Does not significantly affect digoxin serum levels. *KCL* - **Potassium chloride (KCl)** is used to correct **hypokalemia**. - **Hypokalemia** can *potentiate* digoxin toxicity because low potassium increases digoxin binding to the Na+/K+-ATPase pump. - However, KCl supplementation *corrects* hypokalemia and would actually *reduce* toxicity risk, not increase serum digoxin levels. *Atenolol* - **Atenolol** is a **beta-blocker** primarily used to control heart rate and blood pressure. - While it can slow the heart rate like digoxin (additive pharmacodynamic effect), it does not significantly alter the **pharmacokinetics** or serum levels of digoxin. *Amiodarone* - **Amiodarone** is an **antiarrhythmic** that can inhibit P-glycoprotein and increase digoxin levels. - However, in this scenario, **clarithromycin** is more commonly associated with acute elevations in digoxin levels in clinical practice. - Amiodarone interactions are well-known and typically require dose adjustments at initiation.

Question 3: At toxic doses, zero-order kinetics is seen in which of the following substances?

A. Phenytoin (Correct Answer)
B. Valproate
C. Carbamazepine
D. Penicillin

Explanation: ***Phenytoin*** - **Phenytoin** exhibits **zero-order kinetics** at toxic (saturating) doses because its metabolic enzymes become saturated, leading to a constant amount of drug eliminated per unit time rather than a constant fraction - This property makes its plasma concentration disproportionately increase with small dose adjustments once the enzymes are saturated, greatly increasing the risk of **toxicity** - Phenytoin is the **classic example** of capacity-limited metabolism due to saturation of hepatic enzymes (CYP2C9 and CYP2C19) *Penicillin* - Penicillin generally follows **first-order kinetics**, meaning a constant fraction of the drug is eliminated per unit time, and its elimination rate is proportional to its concentration - It is not commonly associated with zero-order kinetics even at higher doses, as its elimination pathways (renal excretion and metabolism) are typically not saturated within therapeutic or moderately toxic ranges *Valproate* - Valproate primarily follows **first-order kinetics** within its therapeutic range, with its elimination rate dependent on the drug concentration - While it can exhibit non-linear kinetics at very high concentrations due to protein binding saturation and enzyme saturation, it is less commonly cited as a classic example of zero-order kinetics compared to phenytoin *Carbamazepine* - Carbamazepine follows **first-order kinetics** within its therapeutic window - It undergoes **autoinduction** of its own metabolism, meaning that with continued dosing, its metabolic enzymes become more active, leading to increased elimination over time rather than saturation-induced zero-order kinetics

Question 4: What is the primary purpose of xenobiotic metabolism?

A. Increase water solubility (Correct Answer)
B. Increase lipid solubility
C. Make them nonpolar
D. None of the above

Explanation: ***Increase water solubility*** - The primary goal of xenobiotic metabolism is to make these foreign compounds more **hydrophilic** (water-soluble). - This increased water solubility facilitates their **excretion** from the body via urine or bile. *Increase lipid solubility* - Increasing **lipid solubility** would make xenobiotics more likely to accumulate in **adipose tissue** and pass through cell membranes, hindering their excretion. - This is the opposite of the desired outcome for xenobiotic elimination. *Make them nonpolar* - Making xenobiotics **nonpolar** would be equivalent to increasing their lipid solubility, as nonpolar molecules tend to be lipid-soluble. - This would impede excretion and potentially lead to **bioaccumulation**, which is harmful. *None of the options* - This option is incorrect because xenobiotic metabolism specifically aims to increase **water solubility** for elimination.

Question 5: Which statement best describes first-order kinetics in pharmacokinetics?

A. Absorption of the drug is independent of the serum concentration
B. Elimination of the drug is proportional to the serum concentration (Correct Answer)
C. Absorption of the drug is proportional to the serum concentration
D. Elimination of the drug is independent of the serum concentration

Explanation: ***Elimination of the drug is proportional to the serum concentration*** - In **first-order kinetics**, a **constant fraction** (or percentage) of the drug is eliminated per unit of time. - This means that as the **serum drug concentration** increases, the absolute amount of drug eliminated per unit time also increases proportionally. *Absorption of the drug is independent of the serum concentration* - Drug absorption is generally driven by factors like **concentration gradient**, surface area, and blood flow, and while it can be influenced by drug concentration, this statement does not define first-order kinetics of *elimination*. - This statement is not the primary characteristic distinguishing first-order from zero-order kinetics regarding drug disposition. *Elimination of the drug is independent of the serum concentration.* - This describes **zero-order kinetics**, where a **constant amount** of drug is eliminated per unit of time, regardless of the serum concentration. - In zero-order kinetics, the elimination rate becomes saturated, so the elimination process cannot keep up with higher drug concentrations. *Absorption of the drug is proportional to the serum concentration* - While drug absorption can be proportional to the concentration (especially through passive diffusion), first-order kinetics specifically refers to the **elimination phase** of pharmacokinetics. - The rate of absorption can be a complex process and is not the defining characteristic for distinguishing first-order from zero-order *elimination*.

Question 6: A 60-year-old patient with atrial fibrillation is prescribed digoxin. Which of the following is the MOST common EARLY side effect of digoxin?

A. Nausea and vomiting (Correct Answer)
B. Hypertension
C. Visual disturbances
D. Hyperkalemia

Explanation: ***Nausea and vomiting*** - **Gastrointestinal symptoms** such as nausea, vomiting, and anorexia are the **most common early signs** of **digoxin toxicity** due to its effect on the **chemoreceptor trigger zone**. - These symptoms can occur even at therapeutic levels, especially in susceptible individuals or with slight increases in concentration. - GI symptoms typically appear **before** other manifestations of toxicity, making them important early warning signs. *Hypertension* - Digoxin primarily affects **cardiac contractility** and **heart rate**, and it is not typically associated with causing **hypertension**. - In fact, digoxin can somewhat lower blood pressure due to its effects on **cardiac output** and **vasodilation** in some circumstances, though this is not its primary mechanism or side effect. *Visual disturbances* - **Visual disturbances**, including blurred vision, halos around lights, and changes in color perception (e.g., **yellow-green halos**), are a classic and **common symptom of digoxin toxicity**. - However, these typically appear **later** than gastrointestinal symptoms and often occur after or concurrently with GI manifestations. - While significant indicators of toxicity, they are not usually the **earliest** warning sign. *Hyperkalemia* - Digoxin inhibits the **Na+/K+-ATPase pump**, which can lead to **intracellular sodium accumulation** and **extracellular potassium accumulation**. However, **hyperkalemia** is primarily seen in cases of **acute, severe digoxin toxicity** or in patients with **renal impairment**. - More commonly, **hypokalemia** can actually potentiate digoxin's effects and increase the risk of toxicity, rather than digoxin directly causing hyperkalemia at therapeutic or mildly toxic levels.

Question 7: Which of the following are CYP3A inhibitors?

A. Ritonavir
B. Amiodarone
C. Verapamil
D. Both a and c (Correct Answer)

Explanation: ***Both a and c (Ritonavir and Verapamil)*** - **Ritonavir** is a **potent CYP3A4 inhibitor**, one of the strongest known, commonly used as a pharmacokinetic booster for other protease inhibitors to increase their bioavailability - **Verapamil** is a **calcium channel blocker** that acts as a **moderate CYP3A4 inhibitor**, leading to clinically significant drug interactions requiring dose adjustments - Both drugs have **clinically relevant and well-established** CYP3A4 inhibitory effects *Ritonavir alone* - While correct that Ritonavir is a potent CYP3A4 inhibitor, this option is incomplete as it excludes Verapamil - Ritonavir's inhibitory effect is so strong that it can increase plasma concentrations of co-administered CYP3A4 substrates by several-fold *Amiodarone* - Amiodarone is primarily a **potent inhibitor of CYP2C9, CYP2D6, and P-glycoprotein** - While it does have **weak to moderate CYP3A4 inhibitory activity**, this effect is **less clinically significant** compared to its effects on other CYP enzymes - In the context of clinically important CYP3A4 inhibitors, Ritonavir and Verapamil are more relevant examples *Verapamil alone* - While correct that Verapamil is a CYP3A4 inhibitor, this option is incomplete as it excludes Ritonavir - Verapamil can increase plasma concentrations of drugs like simvastatin, cyclosporine, and other CYP3A4 substrates

Question 8: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?

A. Amiodarone + Atorvastatin
B. Carbamazepine + Atorvastatin
C. Atorvastatin + Itraconazole (Correct Answer)
D. Phenytoin + Atorvastatin

Explanation: ***Atorvastatin + Itraconazole*** - **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism. - Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**. *Amiodarone + Atorvastatin* - **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole. - While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole. - The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole. *Carbamazepine + Atorvastatin* - **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition. - This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity. *Phenytoin + Atorvastatin* - **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine. - Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.

Question 9: Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?

A. Amoxicillin
B. Cefotaxime
C. Erythromycin (Correct Answer)
D. Cotrimoxazole

Explanation: ***Erythromycin*** - **Erythromycin**, a macrolide antibiotic, is a potent inhibitor of the **cytochrome P450 (CYP450) enzyme system**, specifically **CYP1A2**, which is the primary enzyme responsible for theophylline metabolism. - Co-administration of erythromycin can significantly **increase theophylline levels**, leading to toxicity such as **nausea, vomiting, seizures, or cardiac arrhythmias.** - This interaction is clinically significant and erythromycin should be avoided in patients on theophylline therapy. *Amoxicillin* - **Amoxicillin** is a penicillin-class antibiotic that has minimal interaction with theophylline metabolism. - It does not significantly inhibit the **CYP1A2 enzyme** and is generally considered safe to use with theophylline. *Cefotaxime* - **Cefotaxime**, a third-generation cephalosporin, does not significantly affect the metabolism of theophylline. - It does not inhibit **CYP1A2 enzymes** and is safe for use in patients on theophylline therapy. *Cotrimoxazole* - **Cotrimoxazole** (trimethoprim/sulfamethoxazole) may slightly increase theophylline levels by inhibiting some CYP450 isoenzymes, but its effect is generally less pronounced than that of erythromycin. - While caution and monitoring are advised, it is not as strongly contraindicated as erythromycin due to a lower risk of significant toxicity in most cases.

Question 10: Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?

A. Indinavir
B. Ritonavir (Correct Answer)
C. Lamivudine
D. Efavirenz

Explanation: ***Ritonavir (Correct Answer)*** - **Ritonavir** is the most critical drug to avoid due to severe drug-drug interactions with **rifampicin** - **Rifampicin** is a potent CYP3A4 inducer that dramatically reduces ritonavir plasma concentrations by 75-90%, rendering it completely ineffective - Ritonavir is commonly used as a pharmacokinetic booster for other protease inhibitors, making this interaction particularly significant - **Contraindicated** with rifampicin-based TB regimens *Indinavir* - Also a protease inhibitor metabolized via CYP3A4 - Should also be **avoided with rifampicin** as levels are reduced by approximately 90% - However, indinavir is rarely used in modern ART regimens due to high pill burden, need for dietary restrictions, and significant side effects (nephrolithiasis) - Less commonly used than ritonavir, making ritonavir the better answer *Lamivudine* - Nucleoside reverse transcriptase inhibitor (NRTI) with **renal elimination** - Not metabolized by CYP450 enzymes - **No significant interactions** with rifampicin or other anti-TB drugs - Safe and commonly used in TB/HIV co-infection *Efavirenz* - Non-nucleoside reverse transcriptase inhibitor (NNRTI) that **can be safely co-administered** with rifampicin - Standard dose (600 mg daily) is generally adequate, though some guidelines recommend considering 800 mg in patients >60 kg - **Preferred NNRTI** for TB/HIV co-infection according to WHO guidelines - Well-studied and effective combination with rifampicin-based TB therapy

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free